Posters

Real-life Experience with Ceftobiprole in Canada: Results from the CLEAR (Canadian LEadership on Antimicrobial Real-life Usage) Registry

G Zhanel, J Kosar, M Baxter, R Dhami, S Borgia, N Irfan, KS MacDonald, G Dow, P Lagacé-Wiens, M Dubé, M Bergevin, Y Keynan, A Lee, Z Chagla, G Girouard, A Walkty, J Karlowsky

PDF 604Kb Download

Real-life Experience with IV Fosfomycin in Canada: Results of the CLEAR (Canadian LEadership on Antimicrobial Real-life Usage) Registry

G Zhanel, J Kosar, A Lee, M Baxter, N Irfan, C Rotstein, G Girouard, M Dubé, A Walkty, JF Tessier, P Wong, J Karlowsky

PDF 531Kb Download

Antimicrobial Susceptibility of 56,936 Pathogens Isolated from Patients in Canadian Hospitals: 15 Years of the CANWARD Study 2007-2021

G.G. Zhanel, M. Baxter, A. Golden, B. Funk, P. Lagacé-Wiens, J. Fuller, R. Davidson, J. Blondeau, S. Poutanen, C. Lavallée, J. Karlowsky, R. Taylor, A. Walkty, D. Bay, F. Schweizer, M.R. Mulvey, G. Golding, The Canadian Antimicrobial Resistance Alliance (CARA) and H. Adam

PDF 642Kb Download

Activity of Cefiderocol against >1,000 Isolates of Pseudomonas aeruginosa with Extensively Drug-Resistant (XDR), Multidrug-Resistant (MDR), β-Lactam-, Ciprofloxacin-, and Colistin-Non-Susceptible Phenotypes collected by the CANWARD Surveillance Study from 2007 to 2019

G.G. Zhanel, M.R. Baxter, A. Golden, H.J. Adam, P. Lagacé-Wiens, A. Walkty, F. Schweizer, D. Bay, J.P. Lynch 3rd, M. McCracken, M. Mulvey, J.A. Karlowsky and The Canadian Antimicrobial Resistance Alliance (CARA)

PDF 293Kb Download

Exploration of Genetic Mutations Associated with Reduced Susceptibility to Ertapenem in Enterobacterales Clinical Isolates: CANWARD 2007-2018

A.R. Golden, M. Baxter, L. Mataseje, M.R. Mulvey, H.J. Adam, D. Bay, J.P. Lynch III, A. Walkty, P. Lagacé-Wiens, J.A. Karlowsky and G.G. Zhanel

PDF 293Kb Download

Rates of Extended-Spectrum β-lactamase-Producing (ESBL) Escherichia coli and Klebsiella pneumoniae Continue to Increase in Canada: CANWARD 2007 – 2020

HJ Adam, AJ Denisuik, MR Mulvey, M Baxter, A Golden, PRS Lagacé-Wiens, JA Karlowsky, GG Zhanel and the Canadian Antimicrobial Resistance Alliance (CARA)

PDF 413Kb Download

In Vitro Activity of Fosfomycin Against Bacterial Pathogens Isolated from Urine Specimens in Canada from 2007 to 2020: CANWARD Surveillance Study

G.G. Zhanel, H.J. Adam, M.R. Baxter, A. Walkty, P. Lagacé-Wiens, and J.A. Karlowsky

PDF 346Kb Download

In Vitro Activity of Imipenem-Relebactam against Various Resistance Phenotypes/Genotypes of Enterobacterales and Pseudomonas aeruginosa Isolated from Patients across Canada: CANWARD 2016-2021

G.G. Zhanel, M.R. Baxter, A. Golden, H.J. Adam, P. Lagacé-Wiens, A. Walkty, J.A. Karlowsky and the Canadian Antimicrobial Resistance Alliance (CARA)

PDF 366Kb Download

In Vitro Activity of Sulopenem and Comparative Agents against Bacterial Pathogens Isolated from Canadian Patients with Urinary Tract Infections: CANWARD Surveillance Study 2014-2021

G.G. Zhanel, H.J. Adam, M.R. Baxter, A. Golden, P. Lagacé-Wiens, A. Walkty, J.A. Karlowsky and the Canadian Antimicrobial Resistance Alliance (CARA)

PDF 346Kb Download

Characterization of Streptococcus pneumoniae Serotypes 22F and 33F Causing Invasive Pneumococcal Disease in Canada: SAVE Study 2011-2020

A.R. Golden, H.J. Adam, M. Baxter, J. Schellenberg, I. Martin, W. Demczuk, A. Griffith, J.A. Karlowsky, M.R. Mulvey, G.G. Zhanel, and the Canadian Antimicrobial Resistance Alliance (CARA)

PDF 571Kb Download

Characterization of Streptococcus pneumoniae Serotype 3 Causing Invasive Pneumococcal Disease in Canada: SAVE Study 2011-2020

G.G. Zhanel, A.R. Golden, M.R. Baxter, J. Schellenberg, I. Martin, W. Demczuk, A. Griffith, M.R. Mulvey, J.A. Karlowsky, H.J. Adam, and the Canadian Antimicrobial Resistance Alliance (CARA)

PDF 710Kb Download

Antimicrobial Susceptibility Patterns of Common Invasive Streptococcus pneumoniae Serotypes in Canada: SAVE 2011-2020

H.J. Adam, A.R. Golden, M. Baxter, I. Martin, W. Demczuk, A. Griffith, J.A. Karlowsky, M.R. Mulvey, G.G. Zhanel, and the Canadian Antimicrobial Resistance Alliance (CARA)

PDF 636Kb Download

Vaccine Coverage of PCV-13, PCV-15 and PCV-20 against Antimicrobial-nonsusceptible and Multidrug-resistant Streptococcus pneumoniae (SAVE 2011-2020)

A.R. Golden, H.J. Adam, M. Baxter, I. Martin, W. Demczuk, M.R. Mulvey, J.A. Karlowsky, G.G. Zhanel, and the Canadian Antimicrobial Resistance Alliance (CARA)

PDF 398Kb Download

Real-life Experience with Ceftobiprole in Canada: Results from the CLEAR (Canadian LEadership on Antimicrobial Real-life Usage) Registry

G.G. Zhanel, J. Kosar, M.R. Baxter, R. Dhami, S. Borgia, N. Irfan, K.S. MacDonald, G. Dow, P. R. Lagacé-Wiens, M. Dubé, M. Bergevin, Y. Keynan, A. Lee, A. Walkty, and J.A. Karlowsky

PDF 588Kb Download

Real-life Experience with Ceftolozane-Tazobactam in Canada: Results of the CLEAR (Canadian LEadership on Antimicrobial Real-life Usage) Registry

G.G. Zhanel, R. Dhami, M.R. Baxter, J. Kosar, C. Cervera, N. Irfan, R. Zvonar, S. Borgia, JF. Tessier, G. Dow, R. Ariano, M. Dubé, M. Savoie, S. Lutes, A. Walkty, J.A. Karlowsky

PDF 563Kb Download

Real-life Experience With IV Fosfomycin in Canada: Results of the CLEAR (Canadian LEadership on Antimicrobial Real-life Usage) Registry

G. G. Zhanel, A. Lee, M.R. Baxter, N. Irfan, C. Rotstein, G. Girouard, M. Dubé, A. Walkty, and J.A. Karlowsky

PDF 525Kb Download

In Vitro Activity of Cefepime/Taniborbactam against Ertapenem-Nonsusceptible Enterobacterales Obtained Across Canada: CANWARD 2007-2019

G.G. Zhanel, A. Golden, M.R. Baxter, H.J. Adam, F. Schweizer, P. Lagacé-Wiens, A. Walkty, J.A. Karlowsky and the Canadian Antimicrobial Resistance Alliance (CARA)

PDF 451Kb Download

In Vitro Activity of Imipenem-Relebactam against Various Resistance Phenotypes/Genotypes of Enterobacterales and Pseudomonas aeruginosa Isolated from Patients across Canada: CANWARD 2016-2020

G.G. Zhanel, M.R. Baxter, A. Golden, H.J. Adam, P. Lagacé-Wiens, A. Walkty, J.A. Karlowsky, and the Canadian Antimicrobial Resistance Alliance (CARA)

PDF 378Kb Download

In Vitro Activity of Sulopenem and Comparative Agents against Bacterial Pathogens Isolated from Canadian Patients with Urinary Tract Infections: CANWARD Surveillance Study 2014-2020

G.G. Zhanel, H.J. Adam, M.R. Baxter, A. Golden, P. Lagacé-Wiens, A. Walkty, J.A. Karlowsky and the Canadian Antimicrobial Resistance Alliance (CARA)

PDF 349Kb Download

In Vitro Activity of Fosfomycin Against Bacterial Pathogens Isolated from Urine Specimens in Canada from 2007 to 2019: CANWARD Surveillance Study

G.G. Zhanel, H.J. Adam, M.R. Baxter, A. Golden, N.M. Laing, J.A. Karlowsky

PDF 353Kb Download

Antimicrobial Susceptibility Patterns of Common Invasive Streptococcus pneumoniae Serotypes in Canada: SAVE 2011 - 2017

H.J. Adam, A.R. Golden, M. Baxter, I. Martin, K.A. Nichol, W. Demczuk, M. Mulvey, J.A. Karlowsky, G.G. Zhanel, and the Canadian Antimicrobial Resistance Alliance (CARA)

PDF 333Kb Download

Antimicrobial Susceptibility of 49,319 Pathogens Isolated from Patients in Canadian Hospitals: 12 Years of the CANWARD Study 2007‑2018

G. G. Zhanel, M. Baxter, K. Nichol, A. Golden, R. Hink, P. Lagacé-Wiens, J. Fuller, J. A. Karlowsky, A. Walkty, M. Gilmour, D. Bay, F. Schweizer, R. Domalaon, T. Idowu, A.S. Henni, M. R. Mulvey, G. R. Golding, the Canadian Antimicrobial Resistance Alliance (CARA) and H. Adam

PDF 616Kb Download

Activity of Dalbavancin against Staphylococcus spp., Streptococcus spp., and Enterococcus spp. Isolated by Clinical Laboratories in Canadian Hospitals: CANWARD 2007‑2017

G.G. Zhanel, M. Baxter, K. Nichol, A. Golden, R. Hink, P. Lagacé-Wiens, J.A. Karlowsky, A. Walkty, the Canadian Antimicrobial Resistance Alliance (CARA) and H. Adam

PDF 399Kb Download

Activity of Eravacycline and Comparators Against 15,872 Bacterial Pathogens Isolated from Patients Receiving Care in Canadian Hospitals: CANWARD 2014‑18

G.G. Zhanel, M. Baxter, A.R. Golden, A. Walkty, P.R.S. Lagacé-Wiens, J.A. Karlowsky, H.J. Adam, and the Canadian Antimicrobial Resistance Alliance (CARA)

PDF 469Kb Download

In Vitro Activity of Sulopenem and Comparative Agents against Bacterial Pathogens Isolated from Canadian Patients: CANWARD 2016

G.G. Zhanel, H.J. Adam, M.R. Baxter, P. Lagace-Wiens, A. Walkty, and J.A. Karlowsky

PDF 497Kb Download

Whole Genome Sequencing Analysis of Penicillin-Susceptible, -Intermediate and -Resistant Streptococcus pneumoniae Isolated in Canada, 2011‑2016

R.K. Hink, A.R. Golden, H.J. Adam, I. Martin, W. Demczuk, S. Peterson, K.A. Nichol, P. Van Caeseele, G.J. German, B. Lefebvre, G. Zahariadis, J.B. Gubbay, D. Haldane, J. Minion, R. Gad, M.R. Mulvey, J.A. Karlowsky, G.G. Zhanel, and the Canadian Antimicrobial Resistance Alliance (CARA)

PDF 396Kb Download

In Vitro Activity of Imipenem-Relebactam Against Various Resistance Phenotypes/Genotypes of Enterobacteriaceae and Pseudomonas aeruginosa Isolated from Patients Across Canada: CANWARD 2016‑2018

G.G. Zhanel, H.J. Adam, M.R. Baxter, P.R.S. Lagacé-Wiens, A. Walkty, J.A. Karlowsky, and the Canadian Antimicrobial Resistance Alliance (CARA)

PDF 354Kb Download

Comparison of Streptococcus pneumoniae Serotype 3-ST180 Isolates Collected from Canada and the United States Pre- and Post-PCV-13 Introduction

A.R. Golden, H.J. Adam, I. Martin, W. Demczuk, K. Nichol, J.B. Gubbay, P.N. Levett, M.R. Mulvey, J.A. Karlowsky, G.G. Zhanel, and the Canadian Antimicrobial Resistance Alliance (CARA)

PDF 358Kb Download

Antimicrobial Resistance in Pathogens Isolated from Patients in Canadian Hospitals: CANWARD 2017

M. Baxter, H.J. Adam, M. McCracken, A. Denisuik, G. R. Golding, J.A. Karlowsky, D.J. Hoban and G.G. Zhanel

PDF 381Kb Download

Surveillance and Molecular Characterization of Extended-Spectrum β-Lactamase-Producing Escherichia coli in Canadian Hospitals: Results of the CANWARD Study 2007-2017

A.J. Denisuik, H.J. Adam, A.R. Golden, P. Lagace-Wiéns, M.R. Mulvey, M. Baxter, J.A. Karlowsky, D.J. Hoban, G.G. Zhanel, and the Canadian Antimicrobial Resistance Alliance (CARA)

PDF 1Mb Download

Characterization of Methicillin-Resistant Staphylococcus aureus in Canadian Hospitals from 2007-2017

K.A. Nichol, H.J. Adam, G.R. Golding, M. McCracken, M.R. Baxter, J.A. Karlowsky, D.J. Hoban, G.G. Zhanel, and the Canadian Antimicrobial Resistance Alliance (CARA)

PDF 305Kb Download

Characterization of Non-PCV-13 Streptococcus pneumoniae Serotypes 22F and 33F collected from Invasive Infections in Canada: The SAVE Study 2011-2016

R.K. Hink, A.R. Golden, H.J. Adam, M. Baxter, I. Martin, K.A. Nichol, W. Demczuk, J.A. Karlowsky, D.J. Hoban, M.R. Mulvey, G.G. Zhanel, and the Canadian Antimicrobial Resistance Alliance (CARA)

PDF 386Kb Download

Antimicrobial Susceptibility Patterns of Common Invasive Streptococcus pneumoniae Serotypes in Canada: SAVE 2011 - 2016

H.J. Adam, A.R. Golden, M. Baxter, I. Martin, K.A. Nichol, W. Demczuk, M. Mulvey, J.A. Karlowsky, D.J. Hoban, G.G. Zhanel, and the Canadian Antimicrobial Resistance Alliance (CARA)

PDF 256Kb Download

Trends in Antimicrobial Resistance over Time among Streptococcus pneumoniae Collected from Blood Cultures in Canadian Hospitals: CANWARD 2007-2017

R.K. Hink, H.J. Adam, A.R. Golden, M. Baxter, K.A. Nichol, I. Martin, W. Demczuk, M. Mulvey, J.A. Karlowsky, D. J. Hoban, G. G. Zhanel, and the Canadian Antimicrobial Resistance Alliance (CARA)

PDF 337Kb Download

Antimicrobial Resistance among Streptococcus pneumoniae Collected from Respiratory Cultures in Canadian Hospitals: CANWARD 2007-2017

H.J. Adam, A.R. Golden, M. Baxter, I. Martin, K.A. Nichol, W. Demczuk, M. Mulvey, J.A. Karlowsky, R. Hink, D.J. Hoban, G.G. Zhanel, and the Canadian Antimicrobial Resistance Alliance (CARA)

PDF 313Kb Download

Antimicrobial Susceptibility Testing of Clostridium difficile Ribotypes Infecting Canadian Patients: The Canadian Clostridium difficile Surveillance Study (CAN-DIFF) 2013-2016

J.A. Karlowsky, H.J. Adam, M.R. Baxter, T. Kosowan, K.A. Nichol, N.M. Laing, G. Golding and G.G. Zhanel

PDF 208Kb Download

In Vitro Susceptibility of Escherichia coli Isolated from Urine Specimens of Canadian Outpatients from 2007-2016 to First- and Second-Line Empiric Oral Antimicrobial Agents

J.A. Karlowsky, H.J. Adam, M. R. Baxter, N.M. Laing, A. Walkty, D.J. Hoban, and G.G. Zhanel

PDF 296Kb Download

In Vitro Activity of Imipenem/Relebactam against Various Resistance Phenotypes/Genotypes of Enterobacteriaceae and Pseudomonas aeruginosa Isolated from Patients across Canada: CANWARD 2016/2017

G.G. Zhanel, H.J. Adam, M.R. Baxter, A.J. Denisuik, P.R.S. Lagacé-Wiens, A. Walkty, D.J. Hoban, J.A. Karlowsky, and the Canadian Antimicrobial Resistance Alliance (CARA)

PDF 327Kb Download

Pneumococcal Conjugate Vaccines: Potential Serotypes for Future Formulations

A.R. Golden, H.J. Adam, M. Baxter, I. Martin, W. Demczuk, K. Nichol, J.A. Karlowsky, M.R. Mulvey, G.G. Zhanel, and the Canadian Antimicrobial Resistance Alliance (CARA)

PDF 293Kb Download

In Vitro Activity of Ceftazidime-Avibactam (CAZ-AVI) and Comparators against Gram-Negative Pathogens Isolated from Patients in Canadian Hospitals in 2009-2017: CANWARD Surveillance Study

P. Lagacé-Wiens, H. Adam, M. Baxter, J. Karlowsky, A. Walkty, D. Hoban, A. Denisuik, G. G. Zhanel and the Canadian Antimicrobial Resistance Alliance (CARA)

PDF 156Kb Download

Ceftolozane-Tazobactam Combined with Colistin or Tobramycin Produces Synergistic Inhibition of Multidrug-Resistant (MDR) Clinical Isolates of Pseudomonas aeruginosa Obtained from the CANWARD Surveillance Study 2007-2017

G.G. Zhanel, H.J. Adam, M.R. Baxter, A. Walkty, P.R.S Lagacé-Weins, F. Schweizer, D.J. Hoban, J.A. Karlowsky, and the Canadian Antimicrobial Resistance Alliance (CARA)

PDF 291Kb Download

Antimicrobial Susceptibility of Bacterial Pathogens Isolated from Canadian Intensive Care Units from 2007 to 2016: Results of the CANWARD Study

A.R. Golden, A.J. Denisuik, L.A. Garbutt, H.J. Adam, M. Baxter, P.R.S. Lagacé-Wiens, J.A. Karlowsky, D.J. Hoban, M.R. Mulvey, G.G. Zhanel, and the Canadian Antimicrobial Resistance Alliance (CARA)

PDF 141Kb Download

Antimicrobial Susceptibility of 46,356 Pathogens Isolated from Patients in Canadian Hospitals: 11 Years of the CANWARD Study 2007-2017

G. G. Zhanel, H. Adam, M. Baxter, K. Nichol, A. Denisuik, A. Golden, R. Hink, P. Lagacé-Wiens, J. Fuller, J. A. Karlowsky, A. Walkty, M. Gilmour, D. Bay, F. Schweizer, R. Domalaon, T. Idowu, M. R. Mulvey, G. R. Golding, the Canadian Antimicrobial Resistance Alliance (CARA) and D.J. Hoban

PDF 403Kb Download

In Vitro Activity of Sulopenem, an Oral Penem, against Escherichia coli Isolated from Urine Specimens of Patients Across Canada in 2014-2016

G.G. Zhanel, H.J. Adam, M.R. Baxter, A.J. Denisuik, P. Lagace-Wiens, A. Walkty, D.J. Hoban, S. Puttagunta, M. Dunne, J.A. Karlowsky

PDF 255Kb Download

In Vitro Activity of Ceftazidime-Avibactam (CAZ-AVI) and Comparators against Gram-Negative Pathogens Isolated from Patients in Canadian Hospitals In 2009-2015: CANWARD Surveillance Study

P. Lagacé-Wiens, H. Adam, A. Denisuik, M. Baxter, J. Karlowsky, A. Walkty, D. Hoban, G. G. Zhaneland the Canadian Antimicrobial Resistance Alliance (CARA)

PDF 254Kb Download

Trends in Antimicrobial Susceptibility among Invasive Isolates of Streptococcus pneumoniaein Canada from 2011 to 2015: The SAVE Study

J.A. Karlowsky ,H.J. Adam, A.R. Golden, M.W. Gilmour, M.R. Baxter, I. Martin, K.A. Nichol, W. Demczuk, M.R. Mulvey, D.J. Hoban, G.G. Zhanel, and the Canadian Antimicrobial Resistance Alliance (CARA)

PDF 381Kb Download

SAVE Study: Streptococcus pneumoniae Serotyping and Antimicrobial Susceptibility: Assessment for Vaccine Efficacy in Canada, 2011-2015

H.J. Adam, A. Golden, M. Gilmour, M. Baxter, I. Martin, K.A. Nichol, W. Demczuk, M.Mulvey, J.A. Karlowsky, D.J. Hoban,G.G. Zhanel, and the Canadian Antimicrobial Resistance Alliance (CARA)

PDF 509Kb Download

Comparison of Antimicrobial Resistance Patterns in Streptococcus pneumoniae from Blood and Respiratory Isolates in Canadian Hospitals from 2007-2016

H.J. Adam, A.R. Golden, M. Baxter, K.A. Nichol, I. Martin, W. Demczuk, M. Gilmour, M. Mulvey, J.A. Karlowsky, D.J. Hoban,G.G. Zhanel, and the Canadian Antimicrobial Resistance Alliance (CARA)

PDF 519Kb Download

Characterization by Whole Genome Sequencing of Streptococcus pneumoniae Causing Invasive Infections across Canada SAVE 2011-2014

A.R. Golden, H.J. Adam, I. Martin, W. Demczuk, K. Nichol, M. Gilmour, P. Van Caeseele, G. German,B. Lefebvre, G. Zahariadis, J.B. Gubbay, D. Haldane, G. Horsman,J.A. Karlowsky, M.R. Mulvey, G.G. Zhanel, and the Canadian Antimicrobial Resistance Alliance (CARA)

PDF 849Kb Download

Antifungal Susceptibility and Species Distribution of 1,881 Candidaemia Isolates from Patients in Canadian Hospitals: CANWARD Study 2011-2016

J. Fuller, A. Bull, S. Shokoples, L. Turnbull, H. Adam, M. Baxter,D. J. Hoban,and G. G. Zhanel

PDF 121Kb Download

In Vitro Antimicrobial Activity of Omadacycline, a New Aminomethylcycline, Against Gram-Positive and Gram-Negative Bacterial Pathogens Isolated from Patients Attending Canadian Hospitals in 2015; the CANWARD Study

G. G. Zhanel, H. Adam, M. Baxter, N. Laing, R. Hink, A. Denisuik, P. Lagacé-Wiens, D. J. Hoban, Canadian Antimicrobial Resistance Alliance (CARA) and J. A. Karlowsky

PDF 345Kb Download

Characterization of Meropenem Resistant and MDR Pseudomonas aeruginosa in Canada: Results of the CANWARD 2007-2016 Study

M. McCracken, H. Adam, M. Baxter, A. Walkty, J.A. Karlowsky, G.G. Zhanel, D.A. Boyd,and M.R. Mulvey

PDF 289Kb Download

Activity of Ceftobiprole against Pathogens Isolated from Patients in Canadian Hospitals: CANWARD Study 2015-2016

G. G. Zhanel, H. J. Adam, M. Baxter, A. Denisuik, P. Lagacé-Wiens, A. Walkty, D. J. Hoban, J. A. Karlowsky and The Canadian Antimicrobial Resistance Alliance

PDF 277Kb Download

In Vitro Activity of Plazomicin Against Gram-Negative and Gram-Positive Pathogens Isolated from Patients in Canadian Hospitals in 2011-2015: CANWARD Surveillance Study

G. G. Zhanel, H. J. Adam, M. Baxter, A. Denisuik, A. Walkty, P. R. S. Lagacé-Wiens, F. Schweizer, D. J. Hoban, and J. A. Karlowsky

PDF 277Kb Download

Trends in Antimicrobial Resistance in Canada over Ten Years: Not All Bad News

P. Lagacé-Wiens, H. Adam, M. Baxter, J. Karlowsky, A. Walkty, M. Mulvey , D. Hoban, G. G. Zhaneland the Canadian Antimicrobial ResistanceAlliance (CARA)

PDF 387Kb Download

Antimicrobial Susceptibility of 42,938 Pathogens Isolated from Patients in Canadian Hospitals: CANWARD Study 2007-2016

G.G. Zhanel, H. Adam, M. Baxter, B. Weshnoweski, R. Vashisht, S. Biju, M. Onotera, N. Laing, K. Nichol, A. Denisuik, A. Golden, P. Lagacé-Wiens, J. Fuller,J. A. Karlowsky, A. Walkty, M. Gilmour, D. Bay, F. Schweizer, M. R. Mulvey, G. R. Golding, the Canadian Antimicrobial Resistance Alliance, and D.J. Hoban

PDF 490Kb Download

A Decade of Extended-Spectrum β-Lactamase-Producing Escherichia coli Surveillance in Canadian Hospitals Demonstrates Significant Increases in Prevalence: Results of the CANWARD Study 2007 to 2016

A.J. Denisuik, H.J. Adam, P. Lagacé-Wiens, M.R. Mulvey, M. Baxter, J.A. Karlowsky, M. Gilmour,D.J. Hoban, G.G. Zhanel and the Canadian Antimicrobial Resistance Alliance (CARA)

PDF 1.4Mb Download

Antimicrobial Susceptibility Testing of Clostridium difficile Ribotypes Infecting Canadian Patients: The Canadian Clostridium difficileSurveillance Study (CAN-DIFF) 2013-2015

J.A. Karlowsky, H.J. Adam, M. Chu, T. Kosowan, G. Golding, K.A. Nichol, M.R. Baxter, N.M. Laing, D.J. Hoban, G.G. Zhanel, and the Canadian Antimicrobial Resistance Alliance (CARA)

PDF 292Kb Download

Characterization of Methicillin-Resistant Staphylococcus aureus (MRSA) in Canadian Hospitals from 2007-2016

K.A. Nichol, H.J. Adam, G.R. Golding, M. McCracken, M.R. Baxter, J.A. Karlowsky, D.J. Hoban, G.G. Zhanel, and the Canadian Antimicrobial Resistance Alliance (CARA)

PDF 273Kb Download

Activity of Novel Oxazolidinone Tedizolid against Clinical Gram-Positive Pathogens Collected from Canadian Hospitals: CANWARD 2013-15

A.R. Golden, H.J. Adam, M. Baxter, K.A. Nichol, B. Weshnoweski, R. Vashisht, S. Biju, J.A. Karlowsky, D.J. Hoban,G.G. Zhanel, and the Canadian Antimicrobial Resistance Alliance (CARA)

PDF 299Kb Download

Antimicrobial Susceptibility of 39,816 Pathogens Isolated from Patients in Canadian Hospitals: CANWARD Study 2007-2015

G.G. Zhanel, H.J. Adam, M. Baxter, B. Weshnoweski, R. Vashisht, S. Biju, N. Laing, K. Nichol, A. Denisuik, A. Golden, P. Lagacé-Wiens, J. Fuller, J.A. Karlowsky, A. Walkty, M. Gilmour, D. Bay, F. Schweizer, M.R. Mulvey, G.R. Golding, CARA, and D.J. Hoban

PDF 660Kb Download

Activity of Eravacycline and Comparators against 6,380 Pathogens Isolated from Canadian Hospitals: CANWARD 2014 and 2015

G.G. Zhanel, H. Adam, M. Baxter, B. Weshnoweski, R. Vashisht, S. Biju, A. Golden, A. Denisuik, A. Walkty, P. Lagacé-Wiens, J.A. Karlowsky and D.J. Hoban

PDF 412Kb Download

In Vitro Activity of Fosfomycin against Bacterial Pathogens Isolated from Urine Specimens of Outpatients Attending Emergency Departments in Canada from 2007 to 2014

J.A. Karlowsky, H.J. Adam, M.R. Baxter, N. Laing, B. Weshnoweski, R. Vashisht, and G.G. Zhanel

PDF 368Kb Download

In Vitro Activity of Ceftazidime-Avibactam (CAZ-AVI) and Comparators against Gram-Negative Pathogens Isolated from Patients in Canadian Hospitals in 2009-2015: CANWARD Surveillance Study

P. Lagacé-Wiens, H. Adam, A. Denisuik, M. Baxter, J. Karlowsky, A. Walkty, D. Hoban, G. G. Zhanel and the Canadian Antimicrobial Resistance Alliance (CARA)

PDF 239Kb Download

Rates of Extended-Spectrum β-Lactamase-Producing Escherichia coli Quadruple in Canadian Hospitals Over an 8-year Period: CANWARD 2007-2014

A.J. Denisuik, H.J. Adam, P. Lagacé-Wiens, P.J. Simner, M.R. Mulvey, M. Baxter, M. Gilmour, J.A. Karlowsky, D.J. Hoban, G.G. Zhanel, and the Canadian Antimicrobial Resistance Alliance (CARA)

PDF 312Kb Download

Antimicrobial Susceptibility of Bacterial Pathogens Isolated from Canadian Intensive Care Units from 2007 to 2014: Results of the CANWARD Study

L.A. Garbutt, A.J. Denisuik, H.J. Adam, M. Baxter, P.R.S. Lagacé-Wiens, J.A. Karlowsky, D.J. Hoban, G.G. Zhanel, and the Canadian Antimicrobial Resistance Alliance (CARA)

PDF 345Kb Download

Characterization of Emerging Non-PCV-13 Streptococcus pneumoniae (SPN) Serotypes 22F and 33F Causing Invasive Infections in Canada, 2011-2014

A.R. Golden, H.J. Adam, A. Tsibulski, C. Lawrence, M. Gilmour, M. Baxter, I. Martin, K.A. Nichol, W. Demczuk, J.A. Karlowsky, D.J. Hoban, G.G. Zhanel, and the Canadian Antimicrobial Resistance Alliance (CARA)

PDF 657Kb Download

Antimicrobial Resistance in Streptococcus pneumoniae Isolated in Canada: Comparison of Blood and Respiratory Isolates, CANWARD 2007-2014

A.R. Golden, H.J. Adam, M. Baxter, K.A. Nichol, I. Martin, W. Demczuk, M. Gilmour, J.A. Karlowsky, D.J. Hoban, G.G. Zhanel, and the Canadian Antimicrobial Resistance Alliance (CARA)

PDF 696Kb Download

Characterization of the 10 Most Common Serotypes Causing Invasive Pneumococcal Disease in Canada, 2011-2014

A.R. Golden, H.J. Adam, J. Klassen, M. Gilmour, M. Baxter, I. Martin, K.A. Nichol, W. Demczuk, J. Embree, J.A. Karlowsky, D.J. Hoban, G.G. Zhanel, and the Canadian Antimicrobial Resistance Alliance (CARA)

PDF 270Kb Download

In Vitro Activity of Tedizolid against Gram-Positive Pathogens Isolate in Canadian Hospitals: CANWARD 2013-15

A.R. Golden, H.J. Adam, M. Baxter, K.A. Nichol, B. Weshnoweski, R. Vashisht, S. Biju, J.A. Karlowsky, D.J. Hoban, G.G. Zhanel, and the Canadian Antimicrobial Resistance Alliance (CARA)

PDF 294Kb Download

Activity of Eravacycline and Comparators against 3,174 Pathogens Isolated from Canadian Hospitals: CANWARD 2014

G.G. Zhanel, H. Adam, M. Baxter, B. Weshnoweski, R. Vashisht, S. Biju, A. Golden, A. Denisuik, A. Walkty, P. Lagacé-Wiens, J.A. Karlowsky, and D.J. Hoban

PDF 538Kb Download

Pharmacodynamic Activity of Fosfomycin versus Multidrug-Resistant (MDR) Genotypically CharacterizedExtended Spectrum ß-lactamase (ESBL) - and/or Carbapenemase-Producing Escherichia coli using an In vitro Model

G.G. Zhanel, K. Parkinson, S. Higgins, A. Denisuik, H. Adam, J. Pitout, P. Lagacé-Wiens, D.J. Hoban, J.A. Karlowsky, and the Canadian Antimicrobial Resistance Alliance (CARA)

PDF 303Kb Download

Antimicrobial Susceptibility of 36,607 Pathogens Isolated from Patients in Canadian Hospitals: CANWARD Study 2007-2014

G.G. Zhanel, H.J. Adam, M. Baxter, B. Weshnoweski, R. Vashisht, M. Ismath, R. Hink, K. Nichol, A. Denisuik, A.Golden, P. Lagacé-Wiens, J.A. Karlowsky, M. Gilmour, D. Bay, M.R. Mulvey, and the Canadian Antimicrobial Resistance Alliance (CARA)

PDF 619Kb Download

Current Epidemiology and Antimicrobial Resistance of Streptococcus pneumoniae (SPN) in Canada: SAVE 2014

H.J. Adam, A. Golden, M. Gilmour, M. Baxter, I. Martin, K.A. Nichol, W. Demczuk, J.A. Karlowsky, D.J. Hoban, G.G. Zhanel, and the Canadian Antimicrobial Resistance Alliance (CARA)

PDF 424Kb Download

Pathogens and Their Antimicrobial Resistance Patterns in Emergency Departments (EDs) across Canada: CANWARD 2007-2014

K.J. Thompson, H.J. Adam, M. Baxter, P.R.S. Lagacé-Wiens, J.A. Karlowsky, A. Walkty, D.J. Hoban, the Canadian Antimicrobial Resistance Alliance (CARA), and G.G. Zhanel

PDF 292Kb Download

Characterization of Community- and Healthcare-Associated Methicillin-Resistant Staphylococcus aureus (MRSA) in Canadian Hospitals from 2007-2014

K.A. Nichol, H.J. Adam, G.R. Golding, M. McCracken, M.R. Baxter, M.W. Gilmour, J.A. Karlowsky, D.J. Hoban, G.G. Zhanel, and the Canadian Antimicrobial Resistance Alliance (CARA)

PDF 341Kb Download

Activity of Telavancin against Gram-Positive Cocci from Canadian Hospitals using Revised CLSI Guidelines: CANWARD 2013 and 2014

K.A. Nichol, H.J. Adam, N. Laing, B. Weshnoweski, R. Vashisht, M.R. Baxter, J.A. Karlowsky, D.J. Hoban, G.G. Zhanel, and the Canadian Antimicrobial Resistance Alliance (CARA)

PDF 248Kb Download

In Vitro Activity of Ceftazidime-Avibactam (CAZ-AVI) and Comparators Against Gram-negative Pathogens Isolated from Patients in Canadian Hospitals in 2009-2014: CANWARD Surveillance Study

P. Lagacé-Wiens, H. Adam, A. Denisuik, M. Baxter, J. Karlowsky, A. Walkty, D. Hoban, G. G. Zhanel, and the Canadian Antimicrobial Resistance Alliance (CARA)

PDF 240Kb Download

Use of 0.002% Polysorbate-80 (PS-80) for Determination of Colistin MICs Produces Results that are Compatible with Colistin Pharmacokinetics/Pharmacodynamics

P. Lagacé-Wiens, J. Karlowsky, R. Ariano, S. Zelenitsky, A. Walkty, D. J. Hoban, the Canadian Antimicrobial Resistance Alliance (CARA) and G. G. Zhanel

PDF 303Kb Download

Antimicrobial Susceptibility of Clinical Isolates of Neisseria gonorrhoeae to Unconventional Antimicrobials with Therapeutic Potential: Results of the Canadian Antimicrobial Resistance Initiative for Neisseria gonorrhoeae (CARING)

P. Lagacé-Wiens, H. Adam, M. Baxter, M. Gilmour, I. Martin, M. R. Mulvey, J. Karlowsky, D. J. Hoban, the Canadian Antimicrobial Resistance Alliance (CARA), and G. G. Zhanel

PDF 226Kb Download

Ceftaroline (CPT) and Cefazolin (CFZ) MIC Increase is Associated with Vancomycin (VAN) MIC Increase in Methicillin-resistant Staphylococcus aureus (MRSA) but not Methicillin-susceptible Staphylococcus aureus (MSSA). Analysis of 727 Vancomycin-susceptible MRSA and 2888 MSSA Isolates from the CANWARD Study for a Seesaw Effect.

P. Lagacé-Wiens, S. Zelenitsky, R. Ariano, H. Adam, M. Baxter, J. Karlowsky, A. Walkty, D. J. Hoban, the Canadian Antimicrobial Resistance Alliance (CARA) and G. G. Zhanel

PDF 213Kb Download

CANWARD 2013: Antimicrobial Resistance in Pathogens Isolated from Canadian Hospital Clinics, Emergency Rooms, Medical/Surgical Wards and Intensive Care Units

M. Baxter, H.J. Adam, M. McCracken, A. Denisuik, G. Golding, J.A. Karlowsky, D.J. Hoban, and G.G. Zhanel

PDF 217Kb Download

Epidemiology and Antimicrobial Susceptibilities of Pathogens Isolated from Blood Cultures from Canadian Hospitals: CANWARD 2007-2013 Study

P.J. Simner, H. Adam, M. Baxter, A. Denisuik, J.A. Karlowsky, K. Nichol, P. Lagacé-Wiens, M. Gilmour, Canadian Antimicrobial Resistance Alliance, D.J. Hoban and G.G. Zhanel

PDF 494Kb Download

Trends in antimicrobial resistance in Canada over seven years: Not All Bad News?

P. Lagacé-Wiens, H. Adam, M. Baxter, J. Karlowsky, A. Walkty, P. Simner, M. Gilmour, M. Mulvey, D. Hoban, G.G. Zhanel, and the Canadian Antimicrobial Resistance Alliance

PDF 176Kb Download

In vitro activity of Fidaxomicin and its metabolite OP-1118 against clinical isolates of toxin-positive C. difficile cultured from diarrheal stool specimens in Canada: CAN-DIFF 2013

J.A. Karlowsky, S. Vashisht, G. Golding, H. Adam, T. Kosowan, M. Baxter, N. Laing, D.J. Hoban, G.G. Zhanel, and the Canadian Antimicrobial Resistance Alliance (CARA)

PDF 229Kb Download

In vitro activity of CAZ-AVI and comparators against Gram-negative pathogens isolated from patients in Canadian hospitals in 2009-2013: CANWARD surveillance study

P. Lagacé-Wiens, H. Adam, A. Denisuik, M. Baxter, J. Karlowsky, P.J. Simner, R. Vashisht, A. Walkty, D. Hoban, G.G. Zhanel and the Canadian Antimicrobial Resistance Alliance (CARA)

PDF 181Kb Download

In vitro activity of Oritavancin against Gram-Positive pathogens isolated in Canadian hospitals from 2011 to 2013

J.A. Karlowsky, H.J. Adam, M.R. Baxter, B. Weshnoweski, R. Vashisht, D.J. Hoban, and G.G. Zhanel

PDF 223Kb Download

Activity of Telavancin against Gram-Positive Cocci from CANWARD 2007-2013 using previously established and revised CLSI guidelines

K.A. Nichol, H.J. Adam, N. Laing, B. Weshnoweski, R. Vashisht, M.R. Baxter, J.A. Karlowsky, D.J. Hoban and G.G. Zhanel

PDF 280Kb Download

Changing epidemiology of community-associated methicillin-resistant S. aureus (CA-MRSA) in Canadian hospitals from 2007-2013

K.A. Nichol, H.J. Adam, G.R. Golding, M. McCracken, M.R. Baxter, M.W. Gilmour, J.A. Karlowsky, D.J. Hoban, and G.G. Zhanel

PDF 365Kb Download

Denisuik, A – The continued rise of extended-spectrum ß-Lactamase-, AmpC ß-Lactamase-, and carbapenemase-producing E. coli (EC) and K. pneumoniae (KPN) in Canadian hospitals: CANWARD 2007-2013

A.J. Denisuik, H.J. Adam, P. Lagacé-Wiens, P.J. Simner, M.R. Mulvey, M. Baxter, W. MacDougall, M. Gilmour, J.A. Karlowsky, D.J. Hoban and G.G. Zhanel

PDF 270Kb Download

Vancomycin-resistant Enterococci (VRE) in Canadian hospitals: CANWARD 2007-2013

P.J. Simner, H. Adam, M. Baxter, M. Mccracken, M.R. Mulvey, J.A. Karlowsky, K. Nichol, P. Lagacé-Wiens, M. Gilmour, Canadian Antimicrobial Resistance Alliance (CARA), D.J. Hoban and G.G. Zhanel

PDF 317Kb Download

Pharmacodynamic activity of ertapenem vs. multi-drug resistant (MDR) genotypically characterized extended spectrum ß-lactamase (ESBL) producing E. coli at standard and high inocula using an in vitro model

G.G. Zhanel, S. Vashisht, C. Yachison, A. Denisuik, H. Adam, N. Laing, J. Pitout, P. Lagacé-Wiens, D.J. Hoban and J.A. Karlowsky

PDF 306Kb Download

In vitro activity of fosfomycin against bacterial pathogens isolated from outpatient urine specimens in Canada from 2007 to 2013

J.A. Karlowsky, H.J. Adam, M.R. Baxter, J. Dupuis, N. Laing, B. Weshnoweski, R. Vashisht, and G.G. Zhanel

PDF 372Kb Download

Characterization of multi-drug resistant (MDR) and extensively-drug resistant (XDR) S. pneumoniae in Canadian hospitals, 2007-2013

A.R. Golden, B. Fultz, M. Rosenthal, K.A. Nichol, H.J. Adam, M.W. Gilmour, M. Baxter, D.J. Hoban, J.A. Karlowsky, G.G. Zhanel, and Canadian Antimicrobial Resistance Alliance (CARA)

PDF 443Kb Download

Characterization of potentially emerging S. pneumoniae (SPN) non-vaccine serotypes (NVS) 15A, 22F, 33F and 35B in Canada, 2011-13

A.R. Golden, H.J. Adam, T. Denisuik, M.W. Gilmour, M. Baxter, I. Martin, K.A. Nichol, W. Demczuk, D.J. Hoban, G.G. Zhanel, and Canadian Antimicrobial Resistance Alliance (CARA)

PDF 399Kb Download

Ongoing evolution in the epidemiology and antimicrobial resistance of S. pneumoniae in Canada in the PCV-13 Era: SAVE 2013

H.J. Adam, A. Golden, M. Gilmour, M. Baxter, I. Martin, K.A. Nichol, W. Demczuk, R. Vashisht, J.A. Karlowsky, D.J. Hoban, and G.G. Zhanel

PDF 220Kb Download

CANWARD 2012: Antimicrobial Resistance in Pathogens Isolated from Canadian Hospital Clinics, Emergency Rooms, Medical/Surgical Wards and Intensive Care Units

M. Baxter, H.J. Adam, M. McCracken, A. Denisuik, G. Golding, J.A. Karlowsky, D.J. Hoban, and G.G. Zhanel

PDF 773Kb Download

Antifungal Susceptibility of Respiratory Aspergillus Isolates from Canadian Hospitals: Results of the CANWARD 2012 Study

J. Fuller, S. Jiwa, S. Shokoples, L. Turnbull, R. Rennie, M.Baxter, H. Adam, D.J. Hoban, and G.G. Zhanel

PDF 379Kb Download

Golden, A – In Vitro Activity of Tedizolid against Canadian Clinical Gram-Positive Pathogens, Including hVISA and the CDC NARSA Strains

A. Golden, M. Baxter, K.A. Nichol, B. Weshnoweski, R. Vashisht, H.J. Adam, D.J. Hoban and G.G. Zhanel

PDF 297Kb Download

Nichol, K – Changing Epidemiology of Community-Associated Methicillin-Resistant Staphylococcus aureus (CA-MRSA) in Canadian Hospitals from 2007-2012

K.A. Nichol, H.J. Adam, G.R. Golding, M. Mccracken, M. Baxter, C. Yachison, P. Lagacé-Wiens, D.J. Hoban and G.G. Zhanel

PDF 348Kb Download

Adam, H – The Impact of PCV-13: Changes in the Epidemiology and Antimicrobial Resistance of Streptococcus pneumoniae in Canada, 2007-9 versus 2011-12

H.J. Adam, A. Golden, M. Gilmour, M. Baxter, I. Martin, K.A. Nichol, W. Demczuk, D.J. Hoban, and G.G. Zhanel

PDF 199Kb Download

Zhanel, G – Pharmacodynamic Activity of Ertapenem vs. Multi-Drug Resistant (MDR) Genotypically Characterized Extended Spectrum ß-lactamase (ESBL) or KPC or NDM producing Escherichia coli With Reduced Susceptibility or Resistance to Ertapenem Using and in vitro Model

G. G. Zhanel, A. Denisuik, S. Vashisht, C. Yachison, N. Laing, H.J. Adam and D.J. Hoban

PDF 289Kb Download

Denisuik, A - High National Prevalence of Extended Spectrum β-Lactamase Producing Escherichia coli Isolated from Canadian Hospitals Maintained in 2012: CANWARD 2007-2012

A.J. Denisuik, H.J. Adam, P. Lagacé-Wiens, P.J. Simner, M.R. Mulvey, M. Baxter, D.J. Hoban and G.G. Zhanel

PDF 300Kb Download

Zhanel, G - In vitro Activity of Ceftolozane/Tazobactam against 5,715 Gram-Negative and Gram-Positive Pathogens Isolated from Patients in Canadian Hospitals in 2011 and 2012: CANWARD Surveillance Study

G. G. Zhanel, H. J. Adam, M. Baxter, A. Walkty, P. R. S. Lagacé-Wiens, A. Denisuik, B. Weshnoweski, R. Vashisht, D. J. Hoban and J. A. Karlowsky

PDF 354Kb Download

Zhanel, G – In Vitro Activities of Fidaxomicin, Its Metabolite OP-1118, and Comparative Agents Against Clinical Isolates of Toxin-Positive Clostridium difficile Cultured from Diarrheal Stool Specimens in Canada

J.A. Karlowsky, H.J. Adam, M. Baxter, N.M. Laing, D.J. Hoban, P. Lagacé-Wiens, George G. Zhanel

PDF 252Kb Download

Zhanel, G – In Vitro Activity of Fosfomycin Against Urinary Tract Isolates of Escherichia coli Isolated From Patients Across Canada from 2010 to 2013

J.A. Karlowsky, P. R.S. Lagacé-Wiens, B.Weshnoweski, R.Vashisht, A.J. Denisuik, H. J. Adam, M.R. Baxter, D.J. Hoban, And G.G. Zhanel

PDF 278Kb Download

Nichol, K – Activity of Telavancin against 8,686 Gram-Positive Cocci Associated with Infections in Canadian Hospitals from 2007-2012

K.A. Nichol, H.J. Adam, N. Laing, B. Weshnoweski, R. Vashisht, M.R. Baxter, D.J. Hoban And G.G. Zhanel

PDF 178Kb Download

Dramatic Increase in the Prevalence of ESBL-Producing Escherichia coli (EC) in Canadian Hospitals Over a 5-Year Period

A.J. Denisuik, P.J. Simner, F. Tailor, H.J. Adam, P. Lagacé-Wiens, M.R. Mulvey, M. Baxter, D.J. hoban and G.G. Zhanel

PDF 285Kb Download

In Vitro Activity of Plazomicin Against Gram-Negative and Gram-Positive Pathogens Isolated from Patients in Canadian Hospitals in 2011: CANWARD Surveillance Study

G.G. Zhanel, H.J. Adam, M. Baxter, A. Denisuik, P. P. R. Lagacé-Wiens, F. Schweizer, D.J. Hoban, J.A. Karlowsky

PDF 285Kb Download

Antimicrobial Susceptibility of 27,123 Pathogens Isolated from Patients in Canadian Hospitals: CANWARD Study 2007 - 2011

G.G. Zhanel, H.J. Adam, M. Baxter, K. Nichol, A. Denisuik, P. Lagacé-Wiens, A. Walkty, J.A. Karlowsky, F. Schweizer, Canadian Antimicrobial Resistance Alliance-CARA and D.J. Hoban

PDF 285Kb Download

Multi-drug Resistance in the Most Prevalent Invasive Streptococcus pneumoniae (SPN) Serotypes (STs) Post PCV-13 Introduction in Canada

H.J. Adam, M. Gilmour, M. Baxter, I. Martin, L. Scharikow, K.A. Nichol, W. Demczuk, J. Embree, D.J. Hoban, and G.G. Zhanel

PDF 285Kb Download

Continuing Evolution of USA300 (CMRSA10) Community-Associated Methicillin-Resistant Staphylococcus aureus (CA-MRSA) in Canadian Hospitals from 2007-2011

K.A. Nichol, H.J. Adam, M.R. Mulvey, M. McCracken, M. Baxter, A. Onio, D.J. Hoban and G.G. Zhanel

PDF 285Kb Download